ANI Pharmaceuticals (ANIP) on Monday reported Q2 adjusted earnings of $0.13 per diluted share, down from $0.67 a year earlier. Three analysts polled by...
...
ANI Pharmaceuticals (ANIP) said Wednesday it has launched acebutolol hydrochloride capsules, which are the generic version of Sectral. The company said...
| Address | 210 Main Street West Baudette, Minnesota 56623 |
| Phone | +1.218.634.3500 |
| Number of Employees | 299 |
| Recent SEC Filing | 08/08/2022 10-Q |
| President, Chief Executive Officer & Director | Nikhil Lalwani |
| Senior VP-Operations & Product Development | James G. Marken |
| Chief Financial Officer & Senior VP-Finance | Stephen P. Carey |
| Director & Head-Research & Development | Muthusamy Shanmugam |
| Price Open | $35.46 |
| Previous Close | $35.39 |
| 52 Week Range | $22.31 - 60.23 |
| Market Capitalization | $653.0 M |
| Shares Outstanding | 17.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/07/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$3.60 |
| Beta vs. S&P 500 | N/A |
| Revenue | $201.6 M |
| Net Profit Margin | -27.78% |
| Return on Equity | -23.09% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
